Secondary Logo

Journal Logo

November 2013 - Volume 23 - Issue 11
pp: 587-647

No association of the SLC1A2 rs3794087 allele with risk for essential tremor in the Spanish population

García-Martín, Elena; Martínez, Carmen; Alonso-Navarro, Hortensia; More

Pharmacogenetics and Genomics. 23(11):587-590, November 2013.

Measuring the overall genetic component of nevirapine pharmacokinetics and the role of selected polymorphisms: towards addressing the missing heritability in pharmacogenetic phenotypes?

Micheli, Janine E.; Chinn, Leslie W.; Shugarts, Sarah B.; More

Pharmacogenetics and Genomics. 23(11):591-596, November 2013.

ERCC1 C8092A (rs3212986) polymorphism as a predictive marker in esophageal cancer patients treated with cisplatin/5-FU-based neoadjuvant therapy

Rumiato, Enrica; Cavallin, Francesco; Boldrin, Elisa; More

Pharmacogenetics and Genomics. 23(11):597-604, November 2013.

Impact of genetic and clinical factors on dose requirements and quality of anticoagulation therapy in Polish patients receiving acenocoumarol: dosing calculation algorithm

Wolkanin-Bartnik, Jolanta; Pogorzelska, Hanna; Szperl, Malgorzata; More

Pharmacogenetics and Genomics. 23(11):611-618, November 2013.

CYP2D6 poor metabolizer status might be associated with better response to risperidone treatment

Almoguera, Berta; Riveiro-Alvarez, Rosa; Lopez-Castroman, Jorge; More

Pharmacogenetics and Genomics. 23(11):627-630, November 2013.